These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19567518)

  • 1. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
    Vassiliadi DA; Barber TM; Hughes BA; McCarthy MI; Wass JA; Franks S; Nightingale P; Tomlinson JW; Arlt W; Stewart PM
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T; Honour JW; Conway GS
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
    Fassnacht M; Schlenz N; Schneider SB; Wudy SA; Allolio B; Arlt W
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2760-6. PubMed ID: 12788885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
    Rodin A; Thakkar H; Taylor N; Clayton R
    N Engl J Med; 1994 Feb; 330(7):460-5. PubMed ID: 8289851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
    Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R
    J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
    Gambineri A; Vicennati V; Genghini S; Tomassoni F; Pagotto U; Pasquali R; Walker BR
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
    Chen MJ; Han DS; Yang JH; Yang YS; Ho HN; Yang WS
    Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
    Silfen ME; Shackleton CH; Manibo AM; Levine LS; Sekhar D; McMahon DJ; Oberfield SE
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4647-51. PubMed ID: 12364451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
    Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.
    Gambineri A; Fanelli F; Tomassoni F; Munarini A; Pagotto U; Andrew R; Walker BR; Pasquali R
    Eur J Endocrinol; 2014 Jul; 171(1):47-57. PubMed ID: 24743397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
    Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
    Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
    J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
    Svendsen PF; Madsbad S; Nilas L; Paulsen SK; Pedersen SB
    Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
    Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian 11β-hydroxysteroid dehydrogenase (11βHSD) activity is suppressed in women with anovulatory polycystic ovary syndrome (PCOS): apparent role for ovarian androgens.
    Michael AE; Glenn C; Wood PJ; Webb RJ; Pellatt L; Mason HD
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3375-83. PubMed ID: 23678035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.